Literature DB >> 20009524

PATH Malaria Vaccine Initiative (MVI): perspectives on the status of malaria vaccine development.

Ashley J Birkett1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20009524     DOI： 10.4161/hv.6.1.10462

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


× No keyword cloud information.
  9 in total

1.  Malaria Infection and Gametocyte Carriage Rates in Preparation for Transmission Blocking Vaccine Trials in Bancoumana, Mali.

Authors:  Mahamadoun Hamady Assadou; Issaka Sagara; Sara A Healy; Merepen Agnes Guindo; Mamady Kone; Sintry Sanogo; M'Bouye Doucoure; Sekouba Keita; Ruth D Ellis; Yimin Wu; Freda Omaswa; Patrick E Duffy; Ogobara K Doumbo
Journal:  Am J Trop Med Hyg       Date:  2017-07       Impact factor: 2.345

2.  RALP1 is a rhoptry neck erythrocyte-binding protein of Plasmodium falciparum merozoites and a potential blood-stage vaccine candidate antigen.

Authors:  Daisuke Ito; Tomoyuki Hasegawa; Kazutoyo Miura; Tsutomu Yamasaki; Thangavelu U Arumugam; Amporn Thongkukiatkul; Satoru Takeo; Eizo Takashima; Jetsumon Sattabongkot; Eun-Taek Han; Carole A Long; Motomi Torii; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2013-09-03       Impact factor: 3.441

3.  Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization.

Authors:  Takeshi Miyata; Tetsuya Harakuni; Takafumi Tsuboi; Jetsumon Sattabongkot; Hideyasu Kohama; Mayumi Tachibana; Goro Matsuzaki; Motomi Torii; Takeshi Arakawa
Journal:  Infect Immun       Date:  2010-06-28       Impact factor: 3.441

4.  N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity.

Authors:  Mayumi Tachibana; Yimin Wu; Hideyuki Iriko; Olga Muratova; Nicholas J MacDonald; Jetsumon Sattabongkot; Satoru Takeo; Hitoshi Otsuki; Motomi Torii; Takafumi Tsuboi
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

5.  Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen.

Authors:  Thangavelu U Arumugam; Satoru Takeo; Tsutomu Yamasaki; Amporn Thonkukiatkul; Kazutoyo Miura; Hitoshi Otsuki; Hong Zhou; Carole A Long; Jetsumon Sattabongkot; Jennifer Thompson; Danny W Wilson; James G Beeson; Julie Healer; Brendan S Crabb; Alan F Cowman; Motomi Torii; Takafumi Tsuboi
Journal:  Infect Immun       Date:  2011-09-06       Impact factor: 3.441

6.  Willingness to accept malaria vaccine among caregivers of under-5 children in Southwest Ethiopia: a community based cross-sectional study.

Authors:  Getachew Asmare
Journal:  Malar J       Date:  2022-05-12       Impact factor: 3.469

7.  Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds.

Authors:  Dari F Da; Saurabh Dixit; Jetsumon Sattabonkot; Jianbing Mu; Luc Abate; Bhanumati Ramineni; Jean Bosco Ouedraogo; Nicholas J MacDonald; Michael P Fay; Xin-zhuan Su; Anna Cohuet; Yimin Wu
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

8.  High-Level Expression, Purification and Characterization of A Recombinant Plasmodium vivax Apical Membrane Antigen 1: Implication for vivax Malaria Vaccine Development.

Authors:  Maryam Salavatifar; Sedigheh Zakeri; Nasim Hayati Roodbari; Navid Dinparast Djadid
Journal:  Cell J       Date:  2015-10-07       Impact factor: 2.479

9.  Genome-wide association analysis identifies genetic loci associated with resistance to multiple antimalarials in Plasmodium falciparum from China-Myanmar border.

Authors:  Zenglei Wang; Mynthia Cabrera; Jingyun Yang; Lili Yuan; Bhavna Gupta; Xiaoying Liang; Karen Kemirembe; Sony Shrestha; Awtum Brashear; Xiaolian Li; Stephen F Porcella; Jun Miao; Zhaoqing Yang; Xin-Zhuan Su; Liwang Cui
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.